{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:12:04Z","timestamp":1788779524344,"version":"build-2803163510"},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,7,4]],"date-time":"2012-07-04T00:00:00Z","timestamp":1341360000000},"content-version":"vor","delay-in-days":6335,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1995,3]]},"abstract":"<jats:p>1. Theophylline metabolism was studied using seven human cytochrome P\u2010 450 isoforms (CYPs), namely CYP1A1, 1A2, 2A6, 2B6, 2D6, 2E1 and 3A4, and microsomal epoxide hydroxylase (EH), expressed in human B\u2010 lymphoblastoid cell lines. 2. At a high theophylline concentration of 10 mM four CYPs (1A1, 1A2, 2D6, 2E1) catalyzed the metabolism of theophylline. 3. Theophylline had the highest affinity (apparent Km range 0.2\u20101.0 mM) for the CYP1A subfamily and the kinetics of metabolic formation mediated by CYP1A2 indicated substrate\u2010inhibition (Ki range 9\u2010 16 mM). 4. CYP1A2 catalyzed the demethylation of theophylline as well as its hydroxylation, and was associated with the highest intrinsic clearance (1995 l h\u20101 per mol CYP) to 1,3\u2010dimethyluric acid (DMU). Therefore, this isoform can be considered to be the most important enzyme involved in theophylline metabolism in vitro. 5. CYP2E1 was responsible for a relatively high intrinsic clearance by 8\u2010 hydroxylation (289 l h\u20101 per mol CYP). The apparent Km value of this reaction was about 15 mM, suggesting that CYP2E1 may be the low\u2010 affinity high\u2010capacity isoform involved in theophylline metabolism. 6. The affinity of theophylline for CYP1A1 was comparable with that of its homologue 1A2. When induced, the participation of CYP1A1 in theophylline metabolism may be important. 7. CYP2D6 played only a minor role and CYP3A4 was not active in the in vitro metabolism of theophylline. 8. Our findings confirm the major role of CYP1A2 in theophylline metabolism and explain why in vivo the elimination kinetics of theophylline are non\u2010linear and in vitro theophylline metabolism by human liver microsomes does not obey monophasic kinetics. 9. The data suggest also that not only tobacco smoking but also chronic alcohol intake may influence theophylline elimination in man as ethanol induces CYP2E1.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1995.tb04455.x","type":"journal-article","created":{"date-parts":[[2012,7,5]],"date-time":"2012-07-05T05:19:27Z","timestamp":1341465567000},"page":"321-326","source":"Crossref","is-referenced-by-count":138,"title":["Metabolism of theophylline by cDNA\u2010expressed human cytochromes P\u2010450."],"prefix":"10.1111","volume":"39","author":[{"given":"HR","family":"Ha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AU","family":"Freiburghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Follath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,4]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111843"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1976195part1546"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1978244406"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.193"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197706302962603"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1977213310"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199120010-00005"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/cpt1979265660","article-title":"Effect of allopurinol on theophylline metabolism and clearance","volume":"36","author":"Grygiel JJ","year":"1979","journal-title":"Clin Pharmac Ther"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1982.46"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00613930"},{"key":"e_1_2_1_12_2","first-page":"237","article-title":"Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon\u2010inducible cytochrome P450 in human liver microsomes","volume":"15","author":"Campbell ME","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1987.tb03172.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(88)90423-6"},{"key":"e_1_2_1_15_2","first-page":"31","article-title":"Characterization of human liver cytochromes P\u2010450 involved in theophylline metabolism","volume":"20","author":"Sarkar MA","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199204000-00004"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(92)90282-N"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/S0021-9258(20)82244-3","article-title":"The carbon monoxide\u2010binding pigment of liver microsomes. I. Evidence for its hemo\u2010protein nature","volume":"239","author":"Omura T","year":"1964","journal-title":"J biol Chem"},{"key":"e_1_2_1_19_2","volume-title":"Enzymkinetik. Springer","author":"Lasch J.","year":"1987"},{"key":"e_1_2_1_20_2","first-page":"414","article-title":"Interindividual variations in human liver cytochrome P\u2010450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada T","year":"1994","journal-title":"J Pharmac exp Ther"},{"key":"e_1_2_1_21_2","first-page":"856","article-title":"Characterization of lung microsomal cytochrome P450 1A1 and its role in the oxidation of chemical carcinogens","volume":"41","author":"Shimada T","year":"1992","journal-title":"Mol Pharmac"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840140517"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/331442a0"},{"key":"e_1_2_1_24_2","first-page":"178","article-title":"Theophylline (Theo) biotransformation by human lung microsomes. (Abstract)","volume":"52","author":"Bowen J","year":"1991","journal-title":"Clin Pharmac Ther"},{"key":"e_1_2_1_25_2","first-page":"4875","article-title":"Introduction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: GHA Clowes memorial lecture","volume":"42","author":"Conney AH.","year":"1982","journal-title":"Cancer Res"},{"key":"e_1_2_1_26_2","first-page":"3218","article-title":"Human liver microsomal cytochrome P\u2010450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535\/pSK1002","volume":"49","author":"Shimada T","year":"1989","journal-title":"Cancer Res"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00548764"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.67"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb05064.x"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1993.tb04216.x"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.61"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197803040-00002"},{"key":"e_1_2_1_33_2","first-page":"690","article-title":"Hepatic microsomal enzymes in man and rat: induction and inhibition by ethanol","volume":"169","author":"Rubin E","year":"1969","journal-title":"Science"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00370a001"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.12.4065"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600681106"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.72.1.45"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1995.tb04455.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1995.tb04455.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T15:50:22Z","timestamp":1698249022000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1995.tb04455.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995,3]]}},"alternative-id":["10.1111\/j.1365-2125.1995.tb04455.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1995.tb04455.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,3]]}}}